Recro Pharma to Present at the 16th Annual Needham Healthcare Conference
March 29 2017 - 7:00AM
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty
pharmaceutical company focused on therapeutics for hospital and
other acute care settings, today announced that Gerri Henwood, the
Company’s President and Chief Executive Officer, will present at
the 16th Annual Needham Healthcare Conference on Wednesday, April
5, 2017 at 4:20 pm ET at The Westin New York Grand Central Hotel.
A live and archived webcast of the Needham
presentation will be available on the Presentations page of the
company’s website at http://recropharma.com.
About Recro Pharma, Inc.
Recro is a specialty pharmaceutical company that
operates through two business divisions, an Acute Care, hospital
product division and a revenue-generating contract development and
manufacturing, or CDMO division, located at the Company’s
Gainesville facility. The Acute Care division is primarily focused
on developing innovative products for hospital and other acute care
settings. The Company’s lead product candidate is a proprietary
injectable form of meloxicam, a long-acting preferential COX-2
inhibitor. IV meloxicam has successfully completed four Phase
II clinical trials in the treatment of moderate to severe
post-operative pain and two pivotal Phase III clinical efficacy
trials in patients following bunionectomy and abdominoplasty
surgeries. As injectable meloxicam is in the non-opioid class of
drugs, the Company believes it will overcome many of the issues
associated with commonly prescribed opioid therapeutics, including
respiratory depression, constipation, excessive nausea and
vomiting, as well having no addictive potential while maintaining
meaningful analgesic effects for relief of pain. The Company’s CDMO
division leverages its formulation expertise to develop and
manufacture pharmaceutical products using its proprietary delivery
technologies and other manufacturing services for commercial
partners who commercialize or plan to commercialize these products.
These collaborations can result in revenue streams including
royalties, profit sharing, research and development and
manufacturing fees, which support continued operations for its CDMO
division and it contributes non-dilutive funding for the
development and pre-commercialization activities of its Acute Care
division.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such forward
looking statements reflect Recro's expectations about its future
performance and opportunities that involve substantial risks and
uncertainties. When used herein, the words "anticipate," "believe,"
"estimate," "upcoming," "plan," "target", "intend" and "expect" and
similar expressions, as they relate to Recro or its management, are
intended to identify such forward-looking statements. These forward
looking statements are based on information available to Recro as
of the date of this press release and are subject to a number of
risks, uncertainties, and other factors that could cause Recro’s
performance to differ materially from those expressed in, or
implied by, these forward looking statements. Recro assumes no
obligation to update any such forward-looking statements. Factors
that could cause Recro’s actual performance to materially differ
from those expressed in the forward-looking statements set forth in
this press release include, without limitation: results and timing
of the clinical trials of injectable meloxicam; the ability to
obtain and maintain regulatory approval of injectable meloxicam
and, and the labeling under any such approval, regulatory
developments in the United States and foreign countries; the
Company’s ability to achieve its financial goals, including
financial guidance: the Company’s ability to raise future financing
for continued development and the payment of milestones; the
Company’s ability to pay its debt; customer product performance and
ordering patterns, the performance of third-party suppliers and
manufacturers; the Company’s ability to obtain, maintain and
successfully enforce adequate patent and other intellectual
property protection; and the successful commercialization of
injectable meloxicam. In addition, the forward looking statements
in this press release should be considered together with the risks
and uncertainties that may affect Recro’s business and future
results included in Recro’s filings with the Securities and
Exchange Commission at www.sec.gov. Recro assumes no
obligation to update any such forward looking statements.
CONTACT:
Investor Relations Contact:
Argot Partners
Susan Kim/Natalie Wildenradt
(212) 600-1902
susan@argotpartners.com
natalie@argotpartners.com
Recro Pharma, Inc.
Michael Celano
(484) 395-2413
mcelano@recropharma.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2024 to May 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From May 2023 to May 2024